<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kyntra Bio, Inc. — News on 6ix</title>
<link>https://6ix.com/company/kyntra-bio-inc</link>
<description>Latest news and press releases for Kyntra Bio, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kyntra-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7641551cc36e47533a7c1.webp</url>
<title>Kyntra Bio, Inc.</title>
<link>https://6ix.com/company/kyntra-bio-inc</link>
</image>
<item>
<title>Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 20:05:00 GMT</pubDate>
<description>SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Monday, April 13, 2026, at 1:30 PM EDT. A live webcast of the presentation will be available here. Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Intere</description>
</item>
<item>
<title>Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 16 Mar 2026 20:02:00 GMT</pubDate>
<description>Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinical</description>
</item>
<item>
<title>Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-to-report-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-to-report-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 09 Mar 2026 11:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and we</description>
</item>
<item>
<title>Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026</title>
<link>https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-announces-positive-data-from-the-investigator-sponsored-phase-1b2-study-of-fg-3246-in-combination-with-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-to-be-presented-at-asco-gu-2026</link>
<guid isPermaLink="true">https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-announces-positive-data-from-the-investigator-sponsored-phase-1b2-study-of-fg-3246-in-combination-with-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-to-be-presented-at-asco-gu-2026</guid>
<pubDate>Mon, 23 Feb 2026 22:10:00 GMT</pubDate>
<description>FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPIHigher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards hig</description>
</item>
<item>
<title>Kyntra Bio to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/kyntra-bio-inc/news/kyntra-bio-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 17 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation Date & Time: Thursday, February 26, 2026, 2:40-3:10 PM ET Location: Virtual Webcast: https://event.summitcast.com/view/ Leerink Global Healthcare ConferenceFormat: Corporate Presentation Date & Time</description>
</item>
</channel>
</rss>